AbbVie Inc.
AbbVie Expands Board and Announces Leadership Changes
Summary
AbbVie Inc. expanded its Board of Directors by appointing Thomas J. Falk as a Class III director and announced changes to its leadership, including the election of Robert A. Michael as Chairman, effective July 1, 2025. The company also reported on the outcomes of its 2025 Annual Meeting of Stockholders, including the election of Class I directors, ratification of Ernst & Young LLP as independent auditors, and stockholder votes on executive compensation and governance proposals.
Profitelligence Alerts
Get alerts for ABBV
Be first to know when AbbVie Inc. files with the SEC.
Filing Categories
Advertisement
About AbbVie Inc.
AbbVie Inc. is a prominent biopharmaceutical company that focuses on developing innovative therapies addressing some of the world's most challenging diseases. Originating from a 2013 spinoff of Abbott Laboratories, AbbVie is dedicated to the research and production of pharmaceutical products designed to improve patient outcomes globally. With a robust portfolio, the company specializes in treatments for autoimmune conditions, infectious diseases, oncology, and ophthalmology. Among its flagship products is Humira, widely used for rheumatoid arthritis and inflammatory conditions, which has established AbbVie as a leader in this therapeutic area. The company also invests heavily in research and development, resulting in a pipeline of promising drugs designed to cater to unmet medical needs. AbbVie operates in North America and international markets, serving healthcare providers, researchers, and patients. Its commitment to scientific innovation and high-quality manufacturing standards has positioned it as an influential entity in the healthcare and pharmaceuticals sector.
Official SEC Documents
Advertisement